18-Nov-2026 09:45:24
AVIENCE BIOMEDICALS Q2 FY27 CONCALL: TARGETS ₹75 CR FY27 REVENUE WITH 50%+ GROWTH & 27–28% EBITDA MARGINS; EXPECTS YEIDA PLANT COMMISSIONING BY JANUARY 2027, 200 NEW CDSCO LICENSES & 35–36% LONG-TERM EBITDA MARGINS
AVIENCE BIOMEDICALS Q2 FY27 CONCALL: TARGETS ₹75 CR FY27 REVENUE WITH 50%+ GROWTH & 27–28% EBITDA MARGINS; EXPECTS YEIDA PLANT COMMISSIONING BY JANUARY 2027, 2…